IL290798A - Prodrugs of the tyrosine kinase inhibitor for treating cancer - Google Patents

Prodrugs of the tyrosine kinase inhibitor for treating cancer

Info

Publication number
IL290798A
IL290798A IL290798A IL29079822A IL290798A IL 290798 A IL290798 A IL 290798A IL 290798 A IL290798 A IL 290798A IL 29079822 A IL29079822 A IL 29079822A IL 290798 A IL290798 A IL 290798A
Authority
IL
Israel
Prior art keywords
prodrugs
tyrosine kinase
kinase inhibitor
treating cancer
cancer
Prior art date
Application number
IL290798A
Other languages
Hebrew (he)
Original Assignee
Risen Suzhou Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910818675.XA external-priority patent/CN112442010B/en
Priority claimed from CN201910817505.XA external-priority patent/CN112442009B/en
Priority claimed from CN201910818779.0A external-priority patent/CN112442011B/en
Application filed by Risen Suzhou Pharma Tech Co Ltd filed Critical Risen Suzhou Pharma Tech Co Ltd
Publication of IL290798A publication Critical patent/IL290798A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL290798A 2019-08-30 2022-02-22 Prodrugs of the tyrosine kinase inhibitor for treating cancer IL290798A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910818675.XA CN112442010B (en) 2019-08-30 2019-08-30 Prodrug compounds and application thereof in treating cancers
CN201910817505.XA CN112442009B (en) 2019-08-30 2019-08-30 Deuterated compounds and their use for treating cancer
CN201910818779.0A CN112442011B (en) 2019-08-30 2019-08-30 Prodrug compound and application thereof in treating cancers
US202062994364P 2020-03-25 2020-03-25
PCT/CA2020/051177 WO2021035360A1 (en) 2019-08-30 2020-08-28 Prodrugs of the tyrosine kinase inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
IL290798A true IL290798A (en) 2022-04-01

Family

ID=74684795

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290798A IL290798A (en) 2019-08-30 2022-02-22 Prodrugs of the tyrosine kinase inhibitor for treating cancer

Country Status (5)

Country Link
EP (1) EP4021912A4 (en)
AU (1) AU2020338490A1 (en)
CA (1) CA3147801A1 (en)
IL (1) IL290798A (en)
WO (1) WO2021035360A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
CN106336397A (en) * 2015-07-07 2017-01-18 郭明山 Novel compound for treating ophthalmic diseases
CN106317017A (en) * 2015-07-10 2017-01-11 李建成 Novel compound used for treating ophthalmic diseases
CN106478596A (en) * 2015-08-25 2017-03-08 李建成 A kind of noval chemical compound as treatment ophthalmic diseasess
CA3096963A1 (en) * 2018-04-13 2019-10-17 Hinova Pharmaceuticals Inc. A new method for synthesis of deuterated amide and deuterated sulfonamide

Also Published As

Publication number Publication date
EP4021912A4 (en) 2023-08-23
AU2020338490A1 (en) 2022-03-17
WO2021035360A1 (en) 2021-03-04
EP4021912A1 (en) 2022-07-06
CA3147801A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
EP3781564C0 (en) Pyridazine derivatives for the treatment of cancer
EP3758706A4 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
EP4079735A4 (en) Compound for inhibiting and inducing degradation of egfr kinase
IL280158A (en) Methods of treating cancer with pi3k inhibitor, gdc-0077
EP3226869A4 (en) Kinase inhibitor prodrug for the treatment of cancer
EP3500257A4 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
IL287907A (en) Methods for treating cancer
IL284856A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4081527A4 (en) The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
IL308195A (en) Ras inhibitors for the treatment of cancer
IL287115A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
IL283659A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
EP4108666A4 (en) Multi-target tyrosine kinase inhibitor
IL288522A (en) Egfr inhibitor for the treatment of cancer
EP3630080A4 (en) Use of ezh2 inhibitors for treating cancer
EP3966208A4 (en) Compounds and methods for treating cancer
SG11202107017TA (en) Methods of treating cancer
IL286727A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
EP3843773A4 (en) Inhibition of rip kinases for treating neurodegenerative disorders
IL288665A (en) Methods of treating cancer using prmt5 inhibitors
IL283885A (en) Cxcr7 inhibitors for the treatment of cancer
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
GB201909468D0 (en) Compounds for treating cancer
EP3774799C0 (en) Nek6 kinase inhibitors useful for the treatment of solid tumors